More MS news articles for August 2001

ILEX Oncology Reports Second Quarter Results

Extract from:

Wednesday August 1, 01:02 PM
SAN ANTONIO--(BW HealthWire)


Additionally, ILEX and its partners are working to expand the market potential for Campath(R) by supporting numerous clinical studies in other hematologic malignancies and transplant regimens. The partnership intends to work out a development strategy for Campath(R) in multiple sclerosis by year-end.